A Multi-center, Inpatient and Ambulatory, Phase 2, Double Blind, Randomized, Placebo-controlled Proof of Concept Study of CYR-101 in Patients With DSM-IV Schizophrenia
This Phase II study will test whether CYR-101, a CNS-active compound with novel pharmacological profile and devoid of dopamine D2 receptor binding properties, is efficacious when administered orally in the management of patients with a diagnosis of DSM-IV schizophrenia.
100 项与 Cyrenaic Pharmaceuticals, Inc. 相关的临床结果
0 项与 Cyrenaic Pharmaceuticals, Inc. 相关的专利(医药)
100 项与 Cyrenaic Pharmaceuticals, Inc. 相关的药物交易
100 项与 Cyrenaic Pharmaceuticals, Inc. 相关的转化医学